Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02750592
Other study ID # CAIN457H1301
Secondary ID
Status Completed
Phase Phase 3
First received
Last updated
Start date March 22, 2016
Est. completion date May 16, 2018

Study information

Verified date August 2019
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study was to assess the clinical efficacy, safety and tolerability of secukinumab subcutaneous injections up to 52 weeks in Japanese patients with active AS despite current or previous non-steroidal anti-inflammatory drugs (NSAIDs) and/or anti-tumor necrosis factor (TNF) α therapy. Efficacy and safety data were used to support the registration of secukinumab in Japan for the treatment of active AS.


Recruitment information / eligibility

Status Completed
Enrollment 30
Est. completion date May 16, 2018
Est. primary completion date July 5, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Diagnosis of moderate to severe AS with prior documented radiologic evidence (x-ray or radiologist's report) fulfilling the Modified New York criteria for AS with active AS assessed by BASDAI = 4 (0-10) and spinal pain as measured by VAS= 4 cm (BASDAI question #2) at Baseline

- Patients should have been on NSAIDs at the highest recommended dose for at least 3 months prior to baseline with an inadequate response or failure to respond, or less than 3 months if therapy had to be withdrawn due to intolerance, toxicity or contraindications

- Patients who have been on a TNFa inhibitor (not more than one) must have experienced an inadequate response to previous or current treatment given at an approved dose for at least 3 months prior to baseline or have been intolerant to at least one administration of an anti-TNFa agent

Exclusion Criteria:

- Patients with total ankylosis of the spine

- Patients previously treated with any biological immunomodulating agents except for those targeting TNFa

- Active ongoing inflammatory diseases other than AS that might confound the evaluation of the benefit of secukinumab therapy, including inflammatory bowel disease or uveitis

- Known infection with HIV, hepatitis B or hepatitis C at screening or baseline

Study Design


Intervention

Drug:
Secukinumab 150 mg provided in 1.0 mL pre-filled syringes (PFSs) for sc injection.
Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.

Locations

Country Name City State
Japan Novartis Investigative Site Bunkyo ku Tokyo
Japan Novartis Investigative Site Chuo ku Tokyo
Japan Novartis Investigative Site Kawachinagano Osaka
Japan Novartis Investigative Site Kita-gun Kagawa
Japan Novartis Investigative Site Kitakyushu-city Fukuoka
Japan Novartis Investigative Site Nankoku city Kochi
Japan Novartis Investigative Site Okayama-city Okayama
Japan Novartis Investigative Site Shinjuku-ku Tokyo
Japan Novartis Investigative Site Suita city Osaka
Japan Novartis Investigative Site Tenri Nara

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of SpondyloArthritis International Society 20 Response (ASAS20) This table is ASAS20 response using non-responder imputation for FAS
It assesses the efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline in Japanese patients with active AS based on the proportion of patients achieving an ASAS (Assessment of SpondyloArthritis International Society criteria) 20 response.
The ASAS Response Criteria (ASAS 20) is defined as an improvement of = 20% and = 1 unit on a scale of 10 in at least three of the four main domains and no worsening of = 20% and = 1 unit on a scale of 10 in the remaining domain
week 16
Secondary ASAS 40 Response Rate With Non-responder Imputation (NRI) The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving an ASAS 40 response
ASAS40 response is defined as an improvement of =40% and =2 units on a scale of 10 in at least three of the four ASAS main domains and no worsening at all in the remaining domain
Week 16
Secondary Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 Response Rate The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving Bath Ankylosing Spondylitis Disease Activity (BASDAI) 50 response
The BASDAI 50 is defined as an improvement of at least 50% in the BASDAI compared to baseline
Week 16
Secondary Change in High Sensitivity C-Reactive Protein (hsCRP) hsCRP (mg/L) change from baseline using observed data with log e transformation
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline of high sensitivity C-Reactive Protein (hsCRP)
hsCRP is measured as a marker of inflammation from blood samples during the study
baseline, Week 16
Secondary Number of Participants With ASAS 5/6 Response Criteria The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients meeting the ASAS 5/6 response criteria
The ASAS 5/6 improvement criteria is an improvement of =20% in at least five of all six domains
Week 16
Secondary Mean Change From Baseline in BASDAI From Baseline The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in total BASDAI
The BASDAI consists of a 0 - 10 scale measuring discomfort, pain, and fatigue (0 being no problem and 10 being the worst problem) in response to six questions asked of the patient pertaining to the five major symptoms of AS
Each question (question 1 to 6) is scored from 0 to 10 (0 being no problem and 10 being the worst problem). To give each symptom equal weighting, the mean (average) of the two scores relating to morning stiffness (questions 5 and 6) is taken. The mean of questions 5 and 6 is added to the scores from questions 1-4. The resulting 0 to 50 score is divided by 5 to give a final 0 - 10 BASDAI score.
Baseline, week 16
Secondary Change From Baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS) Score SF-36 PCS, mean change from baseline:
The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in Short Form Health Survey Physical Component Summary (SF-36 PCS)
The SF-36 is an instrument to measure health-related quality of life among healthy patients and patients with acute and chronic conditions
Score range is from 0 (no problems) to 100 (unable to perform the activity)
SF-36 is a 36 item questionnaire which measures Quality of Life across eight domains, which are both physically and emotionally based. Two overall summary scores, the Physical Component Summary (PCS) and Mental Component Summary (MCS) can be computed. In this study, SF-36 PCS is used to assess improvement from baseline. There is no total overall score; scoring is computed for both subscores and summary scores. For subscores and summary scores, 0 =worst score (or quality of life) and 100=best score.
Baseline, week 16
Secondary Change From Baseline in Ankylosing Spondylitis Quality of Life (ASQoL) Score The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the change from baseline in Ankylosing Spondylitis Quality of Life (ASQoL)
The ASQoL is a self-administered questionnaire designed to assess health-related quality of life in adult patients with Ankylosing Spondylitis. The ASQoL contains 18 items with a dichotomous yes/no response option. A single point is assigned for each "yes" response and no points for each "no" response resulting in overall scores that range from 0 (least severity) to 18 (highest severity)
Baseline, week 16
Secondary Proportion of Participants Achieving ASAS Partial Remission The efficacy of secukinumab 150 mg s.c. at Week 16 relative to baseline based on the proportion of patients achieving an ASAS partial remission
The ASAS partial remission criteria are defined as a value not above 2 units in each of the four main domains on a scale of 10
week 16
Secondary Change in Serum Concentration of Secukinumab The assessment of pre dose concentration of secukinumab in Japanese AS patients
An enzyme-linked immunosorbent assay (ELISA) method will be used for bioanalytical analysis of secukinumab in serum, with an anticipated lower limit of quantification (LLOQ) of 80 ng/mL.
Baseline, weeks 4, 16, 24, 52, 60
Secondary Number of Participants With Immunogenicity Against Secukinumab Concentration of anti-secukinumab antibodies
Assessment of immunogenicity against secukinumab by concentration of anti-secukinumab antibodies at pre-dose.
An electrochemiluminescence method was used for the detection of potential anti-secukinumab antibody formation.
week 60
Secondary Number of Participants With Newly Occurring or Worsening Hematology Abnormalities Based on CTCAE Grade, Blood Common Terminology Criteria for Adverse Events (CTCAE) Grades 1-5 refer to severity of the AE:
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)*.
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL**.
Grade 4 Life-threatening consequences; urgent intervention indicated.
Grade 5 Death related to AE.
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.
**Self care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
week 60
Secondary Number of Participants With Newly Occurring or Worsening Chemistry Abnormalities Based on CTCAE Grade Common Terminology Criteria for Adverse Events (CTCAE) Grades 1-5 refer to severity of the AE:
Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated.
Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental Activities of Daily Living (ADL)*.
Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL**.
Grade 4 Life-threatening consequences; urgent intervention indicated.
Grade 5 Death related to AE.
*Instrumental ADL include preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc.
**Self care ADL include bathing, dressing and undressing, feeding self, using the toilet, taking medications, and not bedridden.
week 60
Secondary Participants With Newly Occurring or Worsening Liver Enzyme Abnormalities During the entire safety reporting period, mean values of each liver enzyme parameter stayed within the normal range and were comparable to the baseline values
ALP=Alkaline phosphatase ALT=Alanine aminotransferase AST=Aspartate aminotransferase TBL=Total bilirubin ULN=Upper Limit Normal
week 60
Secondary Number of Participants With Newly Occurring or Worsening Lipid Parameters Abnormalities During the entire safety reporting period, mean values of each lipid parameter stayed within the normal range and were comparable to the baseline values week 60
Secondary Participants With Newly Occurring Notable Abnormalities in Vital Signs Sitting Pulse (bpm) High only (> 100 bpm) Low only (< 60 bpm) Low and High (< 60 bpm and > 100 bpm)
Sitting Diastolic Blood Pressure (BP) (mmHg) High only (= 90 mmHg) Low only (< 60 mmHg) Low and High (< 60 mmHg and = 90 mmHg)
Sitting Systolic Blood Pressure (mmHg) High only (= 140 mmHg) Low only (< 90 mmHg) Low and High (< 90 mmHg and = 140 mmHg)
week 60
See also
  Status Clinical Trial Phase
Terminated NCT02685904 - A Multicentre Study to Evaluate the Efficacy and Safety of ENIA11 in Patients With Ankylosing Spondylitis Phase 3
Completed NCT02186873 - A Study of Golimumab in Participants With Active Ankylosing Spondylitis Phase 3
Completed NCT01668004 - The Incidence of Extra-Articular Manifestations in Participants With Ankylosing Spondylitis Treated With Golimumab (MK-8259-012) Phase 4
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Completed NCT01934933 - Etanercept and Celecoxib Alone/Combined Treatment in Effectiveness and Safety of Active Ankylosing Spondylitis Phase 4
Not yet recruiting NCT04875299 - Optimal Adalimumab Plasma Concentrations in Ankylosing Spondylitis Patients
Completed NCT02763111 - Clinical Trial to Evaluate Efficacy and Safety of Multiple Subcutaneous Injections of Various Doses of BCD-085 in Patients With Active Ankylosing Spondylitis Phase 2
Completed NCT02758782 - NSAIDs Added to Anti-TNF Therapy Versus Anti-TNF Therapy Alone on Progression of Structural Damage in Ankylosing Spondylitis Phase 4
Active, not recruiting NCT02687620 - Does Immunogenicity Have an Influence on the Efficacy of Anti-TNF Therapy in Patients With AS: An Inception Cohort Study
Completed NCT02154425 - A Multicenter, Postmarketing Study Evaluating the Concentration of Cimzia® in Mature Breast Milk of Lactating Mothers Phase 1
Completed NCT01750528 - Prevalence and Progression of Periodontitis in Ankylosing Spondylitis N/A
Completed NCT01463189 - Web-based Support to Manage Arthritis Pain Phase 2
Completed NCT01091675 - Assessment of the Response to Etoricoxib in Patients With Ankylosing Spondylitis and Inadequate Response to ≥2 NSAIDs Phase 3
Completed NCT00844805 - Infliximab for Treatment of Axial Spondyloarthritis (P05336 AM1) Phase 3
Recruiting NCT00747578 - Health-Related Quality of Life and Disease-Related Costs: Comparison Between Ankylosing Spondylitis, Rheumatoid Arthritis and Systemic Lupus Erythematosus in Taiwan N/A
Completed NCT01083693 - Quality of Life Outcomes of HUMIRA in Rheumatoid Arthritis (RA), Psoriatic Arthritis (PsA), Ankylosing Spondylitis (AS) After Unsustainable Response to Biologicals and Disease Modifying Antirheumatic Drugs N/A
Completed NCT00715091 - Effects of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on RAdiographic Damage in Ankylosing Spondylitis Phase 4
Not yet recruiting NCT00517101 - Presence of IBD Specific Antibodies (ASCA, ALCA, ACCA, AMCA) in the Sera of Patients With Spondyloarthropathy N/A
Completed NCT00367211 - Study to Evaluate the Incidence of Gastric Ulcers Following Administration of Either PN 200 or Naproxen in Subjects Who Are at Risk for Developing NSAID-Associated Ulcers. Phase 3
Completed NCT00133315 - TNFalfa Blocking Treatment of Spondylarthropathies Phase 4